Access Bio (XKRX:950130) Total Liabilities : ₩100,022 Mil (As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Access Bio Total Liabilities?

Access Bio's Total Liabilities for the quarter that ended in Jun. 2024 was ₩100,022 Mil.

Access Bio's quarterly Total Liabilities increased from Dec. 2023 (₩103,995.31 Mil) to Mar. 2024 (₩104,101.21 Mil) but then declined from Mar. 2024 (₩104,101.21 Mil) to Jun. 2024 (₩100,021.63 Mil).

Access Bio's annual Total Liabilities increased from Dec. 2021 (₩151,962.41 Mil) to Dec. 2022 (₩259,382.03 Mil) but then declined from Dec. 2022 (₩259,382.03 Mil) to Dec. 2023 (₩103,995.31 Mil).

Access Bio Total Liabilities Historical Data

The historical data trend for Access Bio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Access Bio Total Liabilities Chart

Access Bio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

41,830.38

83,503.44

151,962.41

259,382.03

103,995.31

Access Bio Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Total Liabilities	Get a 7-Day Free Trial															113,898.27	107,765.68	103,995.31	104,101.21	100,021.63

Access Bio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Access Bio's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	44016.853	+	(59714.408	+	264.05199999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	103,995

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	691136.495	-	587141.183
	=	103,995

Access Bio's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	38845.505	+	(60591.87	+	584.25
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	100,022

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	723096.879	-	623075.254
	=	100,022

Access Bio Total Liabilities Related Terms

Thank you for viewing the detailed overview of Access Bio's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Access Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Access Bio Inc (XKRX:950130) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Clyde Road, Suite A, Somerset, NJ, USA, 08873

Website

http://www.accessbio.net

Access Bio Inc is a United States based bio company engaged in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. The products are for the prevention and early diagnosis of infectious diseases. The company's core in vitro-diagnostic technology includes immunochemical, biochemical and molecular products. The company offers products for Rapid Diagnostic Tests including CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM; Biosensors product includes CareStart G6PD Biosensor, and Molecular Diagnostics products include CareStart HPV and CareStart CAH.

Access Bio Headlines

No Headlines